Zydus Cadila Gets First Patch Approval Amid Push Into US

A generic rival to Novartis’ Exelon extended-release treatment for dementia marks Zydus Cadila’s first transdermal patch approval in the US, furthering the Indian firm’s strategy of targeting more complex delivery forms.

Patch
Zydus Cadila has extended its US generics offering with its first approval for a transdermal patch • Source: Shutterstock

Zydus Cadila has expanded its rapidly growing roster of generic approvals in the US with Food and Drug Administration (FDA) clearance for its first transdermal patch, a rivastigmine transdermal system for treating dementia associated with Alzheimer’s and Parkinson’s diseases.

Both US patents listed against the reference brand, Novartis’ Exelon Patch, in the FDA’s Orange Book expired in January this...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Products

More from Generics Bulletin

EMA Greenlights Give Eylea And Stelara Biosimilars Momentum Across Europe

 
• By 

The EMA’s Committee for Medicinal Products for Human Use has issued positive opinions for multiple aflibercept and ustekinumab biosimilars, intensifying competition for Eylea and Stelara respectively in Europe. Meanwhile, a Biocon subsidiary also received a nod for a Neulasta biosimilar.

Accord And Sandoz Remain Frustrated As Dutch Xtandi Patent Is Latest To Hold Firm

 
• By 

In a further setback for generics manufacturers, the District Court of The Hague has upheld the validity of a key Xtandi (enzalutamide) patent and its Dutch supplementary protection certificate, rejecting Sandoz and Accord’s challenge based on lack of inventive step.

Medicines For Europe Sets Out Trade Priorities

 
• By 

As Medicines for Europe gears up for a pair of conferences in Brussels next week, the organization has set out trade policy recommendations to strengthen access to medicines and the competitiveness of EU manufacturing, in a seminar with representatives from the European Commission and member states.